Most Recent PTCB PTCE Exam Dumps

PerUSP standards, a drug with an expiration date ofMarch 2025is consideredvalid until the last day of the month, which isMarch 31, 2025. This applies unless otherwise specified by the manufacturer.

If a drug is labeledMM/YYYY, itremains valid until the last day of that month.

If a drug is labeled with aspecific day (MM/DD/YYYY), itexpires at the end of that day.

A . February 28, 2025 Incorrect; the expiration is at the end ofMarch, not February.

B . March 1, 2025 Incorrect; the drug is stillusable until March 31.

D . March 1, 2026 Incorrect; the drugexpires in March 2025, not 2026.

Expiration Date Rules:Other Answer Choices Explained:Reference:

USP <797> Pharmaceutical Compounding -- Expiration and Beyond-Use Dating (BUD) Guidelines

FDA Drug Expiration Date Regulations

PTCB PTCE Exam Content Outline (Pharmaceutical Storage & Stability)

Naproxen (Aleve, Naprosyn) is a nonsteroidal anti-inflammatory drug (NSAID) used for pain and inflammation.

Reference:FDA NSAID Safety Guidelines.

Clopidogrel (Plavix) is an antiplatelet drug used to prevent blood clots, reducing the risk of heart attack (myocardial infarction) and stroke.

It is commonly prescribed afterstent placement, heart attack, or stroke.

Why Other Options Are Incorrect:

B . GERD?Treated withPPIs or H2 blockers(e.g., omeprazole, ranitidine).

C . Chronic migraines?Treated withbeta-blockers, triptans, or topiramate.

D . Type 2 diabetes?Treated withmetformin, insulin, or GLP-1 agonists.

Reference:AHA Guidelines on Antiplatelet Therapy.

Cefdinir is a third-generation cephalosporin antibiotic commonly used to treat bacterial infections, including otitis media (middle ear infection) in children. It is available in both capsule and suspension forms. However, cefdinir suspension is supplied in different concentrations, typically125 mg/5 mLand250 mg/5 mL.

The prescription provided specifies'Cefdinir suspension 5 mL PO q12h x 10 days', but it does not mention the concentration (strength) of the suspension. Without this crucial information, the pharmacy cannot accurately determine the total dosage the patient will receive. Different strengths would result in significantly different amounts of cefdinir per dose.

For example:

If the prescriber intended125 mg/5 mL, then the patient would receive125 mg per dose (250 mg daily).

If the prescriber intended250 mg/5 mL, then the patient would receive250 mg per dose (500 mg daily).

This discrepancy could lead tounderdosing or overdosing, making it essential for the pharmacy to contact the prescriber to confirm the correct concentration before dispensing.

A . Cefdinir is not available as a suspension. Incorrect. Cefdinir is available inoral suspensionform, typically in 125 mg/5 mL and 250 mg/5 mL concentrations.

C . Cefdinir suspension is not indicated for otitis media. Incorrect. Cefdinir is FDA-approved for the treatment of otitis media in pediatric patients.

D . Cefdinir suspension was prescribed for a child old enough to swallow capsules. Incorrect. While some 8-year-old children may be able to swallow capsules, many pediatric patients prefer liquid formulations, and prescribers often choose suspensions for better compliance.

PTCB PTCE Exam Content Outline -- Medication Order Entry and Fill Process(Ensuring accuracy of prescriptions, including strength and formulation).

FDA Drug Label for Cefdinir-- Indicates available strengths and dosing requirements.

Lexicomp Drug Information for Cefdinir-- Lists the recommended pediatric dosages and available suspension concentrations.

Pharmacology Textbooks (e.g., 'Mosby's Pharmacy Technician: Principles and Practice')-- Reinforce the importance of verifying missing prescription details before dispensing.

Why the Other Answer Choices Are Incorrect:Pharmacy Technician Reference:

Risk Evaluation and Mitigation Strategies (REMS)areFDA-required programsto ensure that thebenefits of certain medications outweigh their risks. REMS programsrestrict prescribing, dispensing, and monitoringdue to the potential for serious side effects or misuse.

Suboxoneis used foropioid dependenceand containsbuprenorphine, apartial opioid agonist, which can causeaddiction, misuse, and respiratory depressionif used improperly.

REMS Requirements for Suboxone:

Prescriber Certification:Only specially certified providers can prescribe Suboxone.

Patient Education:Patients must be informed about the risks of misuse, overdose, and dependence.

Limited Dispensing:Pharmacists must ensure prescriptions meet REMS criteria before dispensing.

A . Xarelto (Rivaroxaban). Incorrect. While Xarelto is an anticoagulant, it isnot under REMS.

C . Warfarin. Incorrect. Warfarin requires monitoring butdoes not have a REMS program.

D . Haloperidol. Incorrect. Haloperidol is an antipsychotic, but itdoes not have a REMS program.

FDA REMS Program List (www.accessdata.fda.gov).

Suboxone REMS Guidelines (www.suboxonerems.com).

PTCB PTCE Exam Content Outline -- REMS and Medication Safety.

Mosby's Pharmacy Technician: Principles and Practice -- REMS Regulations.

Why Is Suboxone (Buprenorphine/Naloxone) Under REMS?Why the Other Answer Choices Are Incorrect:Pharmacy Technician Reference: